QT interval duration and dispersion in children and adolescents treated with ziprasidone

Journal of Clinical Psychiatry

Volumn 72, Issue 6, 2011, Pages 854-860

  Correll, Christoph U ^a,b,c   Lops, Johnny D ^a   Figen, Vicki ^a   Malhotra, Anil K ^a,b,c   Kane, John M ^a,b,c   Manu, Peter ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DISRUPTIVE BEHAVIOR; DRUG BLOOD LEVEL; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; MALE; OBSERVATIONAL STUDY; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; QT DISPERSION; QT INTERVAL; QT PROLONGATION; SCHOOL CHILD; SIDE EFFECT; SYNCOPE; TORSADE DES POINTES;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; PIPERAZINES; POTASSIUM; THIAZOLES; TORSADES DE POINTES;

EID: 79959586204     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m05990yel     Document Type: Article

References (27)

1. DelBello MP, Versavel M, Ice K, et al. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol. 2008;18(5):491-499. doi:10.1089/cap.208.08 PubMed
2. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292-299. doi:10.1097/04583-2030-010 PubMed (Pubitemid 30127607)
3. Malone RP, Delaney MA, Hyman SB, et al. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol. 2007;17(6):779-790. doi:10.1089/cap.206.0126 PubMed (Pubitemid 351158593)
4. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 2005;10(11 suppl 17):s1-s20. PubMed
5. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93. doi:10.2165/023210-2051901-01 PubMed (Pubitemid 40677047)
6. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20. doi:10.1097/chi.0b013e31815b5cb1 PubMed
7. Geodon (ziprasidone) [package insert]. Pfizer, Inc, New York, NY.
8. de Castro MJ, Fraguas D, Laita P, et al. QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2008;18(4):381-383. doi:10.1089/cap.207.015 PubMed
9. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62(11):1649-1671. doi:10.2165/03495- 2026210-06 PubMed (Pubitemid 34848372)
10. Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol. 2005;38(1):10-18. doi:10.1016/j.jelectrocard.204. 09.01 PubMed
11. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259(1):59-69. doi:10.1/j.1365-2796.205.01589.x PubMed
12. Vieweg WVR. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5(5):205-215. doi:10.408/PC.v05n0504 PubMed
13. Bogun F, Chan KK, Harvey M, et al. QT dispersion in nonsustained ventricular tachycardia and coronary artery disease. Am J Cardiol. 1996;77(4):256-259. doi:10.1016/S02-9149(97)89389-7 PubMed (Pubitemid 26059293)
14. Cuddy TE, Halli PS, Tate RB. QT dispersion and heart rate predict the risk of sudden unexpected cardiac death in men: the Manitoba Follow-Up Study. Prev Cardiol. 2009;12(1):27-33. doi:10.1/j.1751-7141.208.016.x PubMed
15. Higham PD, Furniss SS, Campbell RW. QT dispersion and components of the QT interval in ischaemia and infarction. Br Heart J. 1995;73(1):32-36. doi:10.136/hrt.73.1.32 PubMed
16. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J. 1990;63(6):342-344. doi:10.136/hrt.63.6.342 PubMed (Pubitemid 20182179)
17. Tisdale JE, Rasty S, Padhi ID, et al. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes. J Clin Pharmacol. 2001;41(12):1310-1318. doi:10.17/09127012012896 PubMed (Pubitemid 33104898)
18. Strom BL, Eng SM, Faich G et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The ziprasidone observational study of cardiac outcomes (ZODIAC). Am J Psychiatry 2010 Nov 1 [Epub ahead of print]. PubMed
19. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47(3):264-268. doi:10.176/api.psy.47.3.264 PubMed (Pubitemid 46940487)
20. Scahill L, Blair J, Leckman JF, et al. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. J Psychopharmacol. 2005;19(2):205-206. doi:10.17/02698105049042 PubMed (Pubitemid 40577226)
21. Blair J, Scahill L, State M, et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry. 2005;44(1):73-79. doi:10.1097/01.chi.0145372. 61239.b PubMed (Pubitemid 40019202)
22. Biederman J, Mick E, Spencer T, et al. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord. 2007;9(8):888-894. doi:10.1/j.139-5618.207.0450.x PubMed (Pubitemid 350215115)
23. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773. doi:10.101/jama.209.1549 PubMed
24. Correll CU, Frederickson AM, Figen V, et al. The QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2009;259(1):23-27. doi:10.107/s0406-08-0829-4 PubMed
25. Kane JM, Strom BL, Eng SM, et al. Primary and Readjudication Mortality Results From ZODIAC, a Large Simple Trial of Ziprasidone vs Olanzapine in Patients With Schizophrenia. Oral Presentation at the 2nd biennial Schizophrenia International Research Society Conference; April 10-14, 2010; Florence, Italy.
26. Loebel A, Miceli J, Chappell P, et al. Electrocardiographic changes with ziprasidone. J Am Acad Child Adolesc Psychiatry. 2006;45(6):636-637, author reply 638-639. doi:10.1097/01.chi.0215151.5376.5a PubMed
27. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22(1):39-43. (Pubitemid 44901054)